Editorial Article
The Highest-Value Seed Market on Earth Has No Trait Fee
Eight point six billion dollars with no licence layer in it
There is a seed market worth USD 8.60 billion in which essentially no product carries a trait royalty. It is not a niche, it is not a developing-market compromise, and it is the most valuable seed sold anywhere on a per-kilogram basis: vegetables. Every other high-value seed category in the world has a licence stack running through it — a trait fee, a technology fee, a germplasm royalty invoiced separately from the bag. Vegetable seed has almost none, and the reason is that there are no commercial genetically modified vegetables to speak of anywhere in the world.
That is the finding worth arguing about, because it inverts the way the seed industry is usually described. The assumption is that value follows technology, and that the more technology in a seed the more it is worth. The vegetable market is the counter-example: USD 8.60 billion in 2025, rising to USD 13.10 billion by 2033 at 5.40%, with 71.5% of it — USD 6.15 billion — in hybrid seed that earns its price from heterosis, germplasm and disease resistance, and not one dollar of the forecast built on a trait fee.
What the GM map actually contains
Adoption by crop in 2025 is a short list. Cotton is 76.7% genetically modified, soybean 73.9%, maize 35.8%, canola 24.8%, sugar beet 9.7% and alfalfa 3.1%. Across all crops, GM seed covered 28.2% of 765.9 million hectares and was worth USD 26.15 billion in 2025, growing to USD 41.37 billion by 2033. Thirty countries cultivated it.
No vegetable species appears on that list, and it is not for want of technology. It is that the vegetable buyer is a fresh-market consumer or a retailer, the product is eaten close to whole, and the commercial value of a single engineered trait is small against the value that a breeder can already deliver through a resistance locus. When Enza Zaden found a novel high-resistance locus against tomato brown rugose fruit virus, it launched 18 commercial tomato varieties within seven years — none of them a GMO, all of them saleable in every market on earth.
The royalty stack, priced
| Measure | Corn seed | Vegetable seed |
|---|---|---|
| 2025 market value | USD 24.60bn | USD 8.60bn |
| Growth, 2026–2033 | 4.60% | 5.40% |
| Share of the USD 78.40bn seed market | 31.4% | 11.0% |
| Royalty share of a US seed bag | ~70%, against 42% five years earlier | None — no commercial GM vegetables |
| Value implied by that royalty layer | ~USD 17.22bn inside the corn bag | USD 0 |
| Where the premium sits | Trait stack and events | Germplasm, resistance, retail specification |
Read the two columns together. Corn seed is worth nearly three times what vegetable seed is worth, and roughly USD 17.22 billion of the corn figure — the 70% royalty share of a US bag applied across the whole market — is a licence payment for events. Vegetable seed has no equivalent line because there is no event to licence. Its USD 6.15 billion of hybrid value is germplasm sold once, at a price set by how badly the grower needs that specific variety in that specific season.
This is not a technicality about accounting. It changes who earns what. In corn, the owner of the event earns whether or not its germplasm is the best on the field, because the trait travels with the licence. In vegetables, the breeder earns only if the variety performs, every season, in the district where it is sold — and the reward is a seed price that can run to several thousand dollars a kilogram because the alternative is a crop failure in a greenhouse worth several hundred thousand dollars a hectare.
Europe is 0.6% of one market and 24.0% of the other
The single sharpest number in this comparison is where each market sits geographically. Europe is USD 0.15 billion, or 0.6%, of the global GM and biotech seed market. It is USD 2.06 billion, or 24.0%, of the global vegetable seed market — the second-largest region, with the highest value per hectare anywhere, anchored by the Dutch and Mediterranean breeding and propagation cluster. Rijk Zwaan, Enza Zaden, Bejo and Takii are European businesses competing at the top of a market that never needed a regulatory approval to sell its best products.
That is about to be tested, and the test is worth watching closely. Regulation (EU) 2026/1388 was adopted on 17 June 2026, entered into force on 16 July 2026, and applies from 17 July 2028. It splits edited plants into category 1 — those meeting defined equivalence criteria, treated broadly like conventionally bred plants — and category 2, which remains inside the GMO regime. Until July 2028 the existing rules apply to all new genomic techniques, and no crop developed exclusively through NGTs is yet authorised for food or feed in the EU.
So the first market in the world where a gene edit might be sold as a conventional variety is also the market with no royalty stack to defend — and the one where 24.0% of global vegetable seed value sits. The strategic consequence is uncomfortable for anyone who models seed value as technology content. A verified category 1 edit in a vegetable would not create a licence line, because the category is designed precisely so that it does not. It would create a variety, sold at a per-gram price, defended for the life of a retail specification.
Why no trait fee is a strength rather than a gap
The vegetable seed market is not under-monetised because it lacks a technology layer. It is priced where it is because the value is delivered as agronomic certainty and retail compliance, both of which the buyer can see and both of which he pays for in the seed. The top eight breeders hold roughly 62% of value — about USD 5.4 billion of the USD 8.60 billion total — and they spend between a fifth and a quarter of revenue on research: Rijk Zwaan EUR 204 million in FY2024/25, Enza Zaden 27% of revenue. That is a market paying for a pipeline, in cash, at the point of sale.
It is also why the growth rate holds at 5.40% with essentially flat area. In a trait-royalty market, growth comes from stacking one more event into the bag. In a germplasm market, growth comes from stacking one more resistance into the variety, one more retail specification, one more protected-cultivation system. Same outcome on the chart, entirely different mechanism underneath — and the second one does not require a government to approve it first.
Sources and editorial references. The trait-fee comparison between vegetable and GM seed in this piece derives from our vegetable seeds report and GM and biotech seeds report, whose primary sources are ISAAA for GM adoption by crop and country and FAOSTAT for the vegetable and arable area bases against which value per hectare is calculated.
Frequently Asked Questions
Is there any commercial GM vegetable seed?
No. There is no commercially cultivated genetically modified vegetable crop of any scale anywhere in the world. GM adoption in 2025 is concentrated in cotton at 76.7% of world area, soybean at 73.9%, maize at 35.8%, canola at 24.8%, sugar beet at 9.7% and alfalfa at 3.1%. Vegetable seed therefore earns its price from heterosis, germplasm and disease resistance rather than from a licensed event.
How big is the royalty layer in corn seed compared with vegetables?
Roughly 70% of a US corn seed bag is royalty, against 42% five years earlier. Applied across the USD 24.60 billion corn seed market that implies about USD 17.22 billion of licence value inside the corn bag. Vegetable seed has no equivalent, which is why a USD 8.60 billion market and a USD 24.60 billion market have almost nothing in common commercially.
What share of vegetable seed value sits in Europe?
Europe is USD 0.15 billion, or 0.6%, of the global GM and biotech seed market — and USD 2.06 billion, or 24.0%, of the global vegetable seed market. Regulation (EU) 2026/1388 applies from 17 July 2028 and creates a category 1 pathway treating certain edited plants as conventionally bred, which matters most in the one seed category Europe already leads.
Does gene editing change the economics of vegetable breeding?
Not much is known yet. The category 1 route is designed to avoid a GMO-style authorisation, and no crop developed exclusively through new genomic techniques is currently authorised for food or feed in the EU. The immediate commercial effect is a faster, cheaper route to a new variety in a market whose growth already comes from variety turnover rather than from trait licensing.
